Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Lancet (London, England)
|
June 15, 1991
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group
A Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
British Journal of Urology
|
May 23, 1998
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction
J M Buzelin, M C Delauche Cavallier, D Martin, et al.
La Nouvelle Presse Medicale
|
May 15, 1982
[Myasthenic syndrome induced by D-penicillamine. Changes in serum levels of acetylcholine receptor antibodies]
F Woimant, L Benacin, M C Delauche, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|
July 1, 1981
[Condensing plasmacytoma and polyneuropathy. Apropos of a new case]
M C Delauche, J P Clauvel, A Hubault, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|
May 1, 1977
[Diagnostic value of synovial membrane immunofluorescence]
A P Peltier, M C Delauche, L Cyna, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|
October 1, 1977
[Frequency of radiologic chondrocalcinosis in patients over 80 years of age. A prospective study]
M C Delauche, B Stehle, B Cassou, et al.
European Urology
|
January 1, 1997
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group
J M Buzelin, S Roth, C Geffriaud-Ricouard, et al.
British Journal of Urology
|
November 1, 1994
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group
A Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
Annales De Medecine Interne
|
January 1, 1980
[Vascular and obstetrical prognosis after hypertension during pregnancy: value of renal biopsy (author's transl)]
M Beaufils, M C Delauche, L Morel-Maroger, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
August 12, 1999
QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine
M C Delauche-Cavallier, S Chaufour, E Guérault, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Lancet (London, England)
|
June 15, 1991
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group
A Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
British Journal of Urology
|
May 23, 1998
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction
J M Buzelin, M C Delauche Cavallier, D Martin, et al.
La Nouvelle Presse Medicale
|
May 15, 1982
[Myasthenic syndrome induced by D-penicillamine. Changes in serum levels of acetylcholine receptor antibodies]
F Woimant, L Benacin, M C Delauche, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|
July 1, 1981
[Condensing plasmacytoma and polyneuropathy. Apropos of a new case]
M C Delauche, J P Clauvel, A Hubault, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|
May 1, 1977
[Diagnostic value of synovial membrane immunofluorescence]
A P Peltier, M C Delauche, L Cyna, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|
October 1, 1977
[Frequency of radiologic chondrocalcinosis in patients over 80 years of age. A prospective study]
M C Delauche, B Stehle, B Cassou, et al.
European Urology
|
January 1, 1997
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group
J M Buzelin, S Roth, C Geffriaud-Ricouard, et al.
British Journal of Urology
|
November 1, 1994
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group
A Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
Annales De Medecine Interne
|
January 1, 1980
[Vascular and obstetrical prognosis after hypertension during pregnancy: value of renal biopsy (author's transl)]
M Beaufils, M C Delauche, L Morel-Maroger, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
August 12, 1999
QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine
M C Delauche-Cavallier, S Chaufour, E Guérault, et al.
Page
of 4